Lipoprotein-associated phospholipase A2 in coronary heart disease: review and meta-analysis

D Li, L Zhao, J Yu, W Zhang, R Du, X Liu, Y Liu… - Clinica Chimica …, 2017 - Elsevier
Background Risk associations between lipoprotein-associated phospholipase A2 (Lp-PLA2)
and adverse outcomes in patients with coronary heart disease (CHD) remain unclear. The …
被引用次数：63 相关文章

Lipoprotein-associated phospholipase A2 in coronary heart disease: Review and meta-analysis.

D Li, L Zhao, J Yu, W Zhang, R Du, X Liu… - Clinica Chimica Acta; …, 2016 - europepmc.org
Background Risk associations between lipoprotein-associated phospholipase A2 (Lp-PLA2)
and adverse outcomes in patients with coronary heart disease (CHD) remain unclear. The …

Lipoprotein-associated phospholipase A2 in coronary heart disease: Review and meta-analysis

D Li, L Zhao, J Yu, W Zhang, R Du, X Liu, Y Liu… - Clinica Chimica …, 2017 - infona.pl
Risk associations between lipoprotein-associated phospholipase A2 (Lp-PLA2) and
adverse outcomes in patients with coronary heart disease (CHD) remain unclear. The aim of …

[引用][C] Lipoprotein-associated phospholipase A2 in coronary heart disease: Review and meta-analysis

D Li, L Zhao, J Yu, W Zhang, R Du, X Liu, Y Liu… - Clinica Chimica …, 2017 - cir.nii.ac.jp

Lipoprotein-associated phospholipase A2 in coronary heart disease: Review and meta-analysis

D Li, L Zhao, J Yu, W Zhang, R Du… - … journal of clinical …, 2017 - pubmed.ncbi.nlm.nih.gov
Background Risk associations between lipoprotein-associated phospholipase A2 (Lp-PLA2)
and adverse outcomes in patients with coronary heart disease (CHD) remain unclear. The …